Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.
Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.